Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours

BACKGROUND: Cetuximab is often combined with radiotherapy in advanced SCCHN. Alternative routes bypassing inhibition of EGFR with cetuximab may overshadow the efficacy of this combination. We undertook this study to investigate a possible role of dasatinib in this scenario. METHODS: The SCC5, SCC25,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Baro, M, de Llobet, L I, Figueras, A, Skvortsova, I, Mesia, R, Balart, J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2014
Soggetti:
Translational Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4183853/
https://ncbi.nlm.nih.gov/pubmed/25077442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.432
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi